The impact of EGFR subtype combined with TP53 co-mutation status on survival outcomes with front-line osimertinib in non-small cell lung cancer (NSCLC).

doi:10.1016/j.lungcan.2026.109582

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

The impact of EGFR subtype combined with TP53 co-mutation status on survival outcomes with front-line osimertinib in non-small cell lung cancer (NSCLC).

Lung cancer (Amsterdam, Netherlands) - 1 Oct 2026

Kim Hye Sung, Zhang Li, Bodor J Nicholas, Clapper Margie L, Borghaei Hossein, Edelman Martin J, Zhou Yunyun, Cheung Mitchell, Treat Joseph

Abstract excerpt

BACKGROUND: Osimertinib is a standard therapy for EGFR-mutant NSCLC. However, markers to better identify those at risk for poor outcomes are needed. This is the largest study to date evaluating the impact of EGFR subtype combined with TP53 co-mutation status on survival endpoints with front-line osimertinib. METHODS: Patients from a U.S. clinical-genomic database with advanced EGFR-mutant NSCLC receiving...

Read the complete abstract on PubMed

Topics

Humans
Pyrimidines
Indoles
Aniline Compounds
Acrylamides
Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Lung Neoplasms

Tumor Suppressor Protein p53

Female

ErbB Receptors

Mutation

Male

Aged

Middle Aged

Prognosis

Antineoplastic Agents

Protein Kinase Inhibitors

Source

Open in PubMed

Identifiers

PMID: 42660014
DOI: 10.1016/j.lungcan.2026.109582

Genes

TP53
EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 24 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The impact of EGFR subtype combined with TP53 co-mutation status on survival outcomes with front-line osimertinib in non-small cell lung cancer (NSCLC).PMID 42660014Read ↗

Clinical factors and molecular co-alterations impact outcomes in patients receiving first-line osimertinib for EGFR-mutated non-small cell lung cancer.Semantic proximity Read ↗

New therapeutic approaches for EGFR mutated non-small cell lung cancer on osimertinib era.Semantic proximity Read ↗

Osimertinib plus Chemotherapy versus Osimertinib for Patients with Advanced NSCLC Concomitant EGFR and TP53 Mutations: A Prospective Cohort StudySemantic proximity Read ↗

Effect of EGFR-TP53 co-mutation on the efficacy of EGFR-TKIs in patients with advanced NSCLC and therapeutic strategies: A retrospective study.Semantic proximity Read ↗

TP53 co-mutations in EGFR mutated patients in NSCLC stage IV: A strong predictive factor of ORR, PFS and OS in EGFR mt+ NSCLCSemantic proximity Read ↗

TP53 co-mutations as an independent prognostic factor in 2nd and further line therapy—EGFR mutated non-small cell lung cancer IV patients treated with osimertinibSemantic proximity Read ↗

Impact of Tumor Suppressor Gene Co-Mutations on Differential Response to EGFR TKI Therapy in EGFR L858R and Exon 19 Deletion Lung Cancer.Semantic proximity Read ↗

TP53 Co-Mutation Status Association with Clinical Outcomes in Patients with EGFR-Mutant Non-Small Cell Lung CancerSemantic proximity Read ↗

Osimertinib plus anlotinib in untreated, EGFR-mutated, advanced non-small-cell lung cancer with concurrent alterations: a multicenter phase II study.Semantic proximity Read ↗

Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC).Semantic proximity Read ↗

The significance of co-mutations in EGFR-mutated non-small cell lung cancer: Optimizing the efficacy of targeted therapies?Semantic proximity Read ↗

Co-mutation landscape and prognostic impact of genomic complexity in EGFR-mutant non-small cell lung cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.